Lexicon Pharmaceuticals, Inc.

NasdaqCM:LXRX Stock Report

Market Cap: US$792.3m

Lexicon Pharmaceuticals Management

Management criteria checks 3/4

Lexicon Pharmaceuticals' CEO is Mike Exton, appointed in Jul 2024, has a tenure of 1.75 years. total yearly compensation is $3.55M, comprised of 18.3% salary and 81.7% bonuses, including company stock and options. directly owns 0.07% of the company’s shares, worth $558.08K. The average tenure of the management team and the board of directors is 2.4 years and 18.7 years respectively.

Key information

Mike Exton

Chief executive officer

US$3.6m

Total compensation

CEO salary percentage18.31%
CEO tenure1.8yrs
CEO ownership0.07%
Management average tenure2.4yrs
Board average tenure18.7yrs

Recent management updates

Recent updates

Lexicon Pharmaceuticals: 'Hold' As FDA Feedback Allows Pilavapadin For DPNP To Go Forward

Jan 22

Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Shares Climb 28% But Its Business Is Yet to Catch Up

Jan 22
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Shares Climb 28% But Its Business Is Yet to Catch Up

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Dec 18
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28%

Oct 02
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28%

There's Reason For Concern Over Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Massive 34% Price Jump

Jul 28
There's Reason For Concern Over Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Massive 34% Price Jump

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31%

Jun 13
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31%

Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts

May 19
Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts

Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates

May 17
Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates
User avatar

Pilavapadin Trials And LX9851 Development Will Expand Treatment Options

Advancing novel medicines like pilavapadin and LX9851 could significantly impact revenue growth and open high-demand markets.

Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)

Mar 28

Investors Don't See Light At End Of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Tunnel And Push Stock Down 50%

Mar 26
Investors Don't See Light At End Of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Tunnel And Push Stock Down 50%

Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes

Oct 16

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Aug 03

Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much

May 28

CEO Compensation Analysis

How has Mike Exton's remuneration changed compared to Lexicon Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$4mUS$651k

-US$50m

Sep 30 2025n/an/a

-US$69m

Jun 30 2025n/an/a

-US$121m

Mar 31 2025n/an/a

-US$177m

Dec 31 2024US$3mUS$304k

-US$200m

Compensation vs Market: Mike's total compensation ($USD3.55M) is about average for companies of similar size in the US market ($USD3.59M).

Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.

CEO

Mike Exton (55 yo)

1.8yrs
Tenure
US$3,553,953
Compensation

Dr. Michael S. Exton, also known as Mike, Ph D is Chief Executive Officer and Director of Lexicon Pharmaceuticals, Inc. from July 08, 2024. Dr. Exton most recently served as the global cardiometabolic ther...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Exton
CEO & Director1.8yrsUS$3.55m0.070%
$ 558.1k
Scott Coiante
Senior VP & CFO1.3yrsUS$1.56m0.025%
$ 197.0k
Brian Crum
Senior VP15.9yrsUS$1.50m0.10%
$ 801.9k
Wendy McDermott
Senior Vice President of Human Resources4.3yrsUS$1.27m0.066%
$ 519.7k
Craig Granowitz
Senior VP & Chief Medical Officer4.7yrsUS$1.76m0.076%
$ 604.8k
Kristen Alexander
Vice President of Finance & Accounting4.6yrsUS$613.25k0.018%
$ 142.8k
Lisa DeFrancesco
Senior Vice President of Investor Relations & Corporate Communications2.4yrsno data0.022%
$ 175.6k
Suma Gopinathan
Senior Vice President of Discovery1.3yrsno data0.035%
$ 280.8k
Rachel Martens
Senior VP of Partnerships & Corporate Strategyless than a yearno data0.0074%
$ 58.5k
2.4yrs
Average Tenure
54yo
Average Age

Experienced Management: LXRX's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Michael Exton
CEO & Director1.8yrsUS$3.55m0.070%
$ 558.1k
Raymond Debbane
Independent Chairman of the Board18.7yrsUS$196.33k0.45%
$ 3.6m
Samuel Barker
Independent Director26.1yrsUS$188.83k0.029%
$ 232.8k
Philippe Amouyal
Independent Director18.7yrsUS$176.33k0.067%
$ 533.3k
Christopher Sobecki
Independent Director18.7yrsUS$161.33k0.048%
$ 381.2k
Judith Swain
Independent Director18.6yrsUS$173.83k0.020%
$ 159.2k
Alan Nies
Chairman of Medical Advisory Board23.1yrsUS$82.87kno data
Diane Sullivan
Independent Director2.8yrsUS$171.33k0.0087%
$ 68.8k
Ivan H. Cheung
Independent Director1.3yrsUS$171.33kno data
18.7yrs
Average Tenure
66yo
Average Age

Experienced Board: LXRX's board of directors are seasoned and experienced ( 18.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/19 01:36
End of Day Share Price 2026/04/17 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lexicon Pharmaceuticals, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yigal NochomovitzCitigroup Inc
Joseph PantginisH.C. Wainwright & Co.
Andrew TsaiJefferies LLC